|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvalYear
|
2012
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
A08AA10
|
|
gptkbp:brand
|
gptkb:Belviq
|
|
gptkbp:CASNumber
|
616202-92-7
|
|
gptkbp:contraindication
|
pregnancy
severe renal impairment
severe hepatic impairment
|
|
gptkbp:country_withdrawn
|
gptkb:Canada
gptkb:Europe
gptkb:United_States
|
|
gptkbp:developedBy
|
gptkb:Arena_Pharmaceuticals
|
|
gptkbp:drugClass
|
gptkb:anorectic
gptkb:serotonin_receptor_agonist
|
|
gptkbp:eliminationHalfLife
|
11 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstSynthesized
|
2003
|
|
gptkbp:hasInChIKey
|
VVLXBWKOBKWLFI-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C11H14ClN
|
|
gptkbp:hasSMILES
|
Clc1ccc(cc1)CCN2CCOCC2
|
|
gptkbp:legalStatus
|
Withdrawn
|
|
gptkbp:marketedAs
|
gptkb:Eisai
|
|
gptkbp:mechanismOfAction
|
5-HT2C receptor agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
195.692 g/mol
|
|
gptkbp:patent_holder
|
gptkb:Arena_Pharmaceuticals
|
|
gptkbp:pregnancyCategory
|
X
|
|
gptkbp:PubChem_CID
|
CHEMBL2108507
11528182
9700422
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
constipation
dizziness
fatigue
headache
dry mouth
|
|
gptkbp:UNII
|
O8C8VZ6K3E
|
|
gptkbp:usedFor
|
weight loss
|
|
gptkbp:withdrawal_year
|
2020
|
|
gptkbp:withdrawn
|
increased cancer risk
|
|
gptkbp:withdrawn_by
|
gptkb:FDA
|
|
gptkbp:bfsParent
|
gptkb:Belviq
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
lorcaserin
|